LIVONIA, Mich.–(BUSINESS WIRE)–Masco Corporation (NYSE: MAS) will hold a conference call regarding its 2026 third quarter results on Wednesday, October 28 at 8:00 a.m. ET, hosted by President and Chief Executive Officer, Jon Nudi. To join, dial (585) 542-9983 or (833) 461-5787 and enter meeting ID 284633590. Please register five to ten minutes before the call begins. The 2026 third quarter results and supporting materials will be released at 7:00 a.m. ET on October 28 and can be found on the
Tag: Business Wire
LIVONIA, Mich.–(BUSINESS WIRE)–Masco Corporation (NYSE: MAS) will hold a conference call regarding its 2026 third quarter results on Wednesday, October 28 at 8:00 a.m. ET, hosted by President and Chief Executive Officer, Jon Nudi. To join, dial (585) 542-9983 or (833) 461-5787 and enter meeting ID 284633590. Please register five to ten minutes before the call begins. The 2026 third quarter results and supporting materials will be released at 7:00 a.m. ET on October 28 and can be found on the
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Teledyne Technologies Incorporated (NYSE:TDY) announced today that Jason VanWees, Vice Chairman, will be retiring from his current position at Teledyne, effective February 1, 2027, at which point he will be age 55. Jason joined Teledyne prior to the company’s spin-off in 1999 and was named Vice Chairman in 2021. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, has been appointed Corporate Vice President of Investor Rel
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Teledyne Technologies Incorporated (NYSE:TDY) announced today that Jason VanWees, Vice Chairman, will be retiring from his current position at Teledyne, effective February 1, 2027, at which point he will be age 55. Jason joined Teledyne prior to the company’s spin-off in 1999 and was named Vice Chairman in 2021. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, has been appointed Corporate Vice President of Investor Rel
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
MUMBAI, India & CINCINNATI–(BUSINESS WIRE)–Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lo
MUMBAI, India & CINCINNATI–(BUSINESS WIRE)–Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lo
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). The da
RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,” said George Addona, senior vice president,